- PR Newswire•3 days agoNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Feb. 22, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March 1, 2017, ...
- PR Newswire•7 days agoClinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
SAN FRANCISCO and ORLANDO, Fla., Feb. 18, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, ...
- Accesswire•last month
NEW YORK, NY / ACCESSWIRE / January 25, 2017 / The Biotech Industry had a solid start to the year before comments made by President Trump triggered a major selloff within the industry. The iShares NASDAQ ...
NKTR : Summary for Nektar Therapeutics - Yahoo Finance
Nektar Therapeutics (NKTR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||10.28 x 100|
|Ask||16.87 x 200|
|Day's Range||13.04 - 13.46|
|52 Week Range||10.67 - 19.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|